Skip to main content
TipRanks
Go Ultimate75% OFF

Achieve Life Sciences (SP4P) AI Stock Analysis

3 Followers
DE:SP4P

Achieve Life Sciences

(Frankfurt:SP4P)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Focused smoking-cessation pipelineA focused lead program targeting nicotine dependence gives Achieve Life Sciences a clear strategic direction and addresses a defined public-health need. If development and approval succeed, cytisinicline could support a specialized prescription-product business rather than a diversified but unfocused pipeline.
Negative Factors
Minimal revenue and severe lossesThe company has not yet demonstrated a functioning commercial revenue base, while losses are extremely large relative to reported sales. Persistent negative profitability leaves the business dependent on successful clinical and regulatory execution before meaningful operating leverage can emerge.

Achieve Life Sciences (SP4P) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%125%DE:SP4P+48.61%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 604.03M
Dividend Yield
―
Average Volume (3M)
193
Price to Earnings (P/E)
-4.0
Beta (1Y)
1.43
Revenue Growth
―
EPS Growth
5.28%
Country
Germany
Employees
28
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Achieve Life Sciences Business Overview & Revenue Model

Company Description

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a...

Achieve Life Sciences Earnings Call Summary

Earnings Call Date:May 12, 2026(Q1-2026)|% Change Since:22.71%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.

Positive Updates

Transformational Financing
Completed a private placement providing $180 million in upfront capital plus up to $174 million in milestone-based warrants exercisable before and up to 20 trading days after FDA approval, supported by a syndicate of specialist healthcare investors (Frazier, TPG, venBio, Paradigm, Marshall Wace).

Negative Updates

Expected FDA Complete Response Letter (CRL) and Delay
Company announced it expects a CRL on or by the June 20 PDUFA date due to an official action indicated (OAI) classification at a separate third-party manufacturer; this necessitates an NDA resubmission in Q4 2026 and pushes projected approval/launch timing.

Company Guidance

Achieve guided that it expects a complete response letter on or by its June 20, 2026 PDUFA date and plans to resubmit the NDA in Q4 2026 naming Adare as primary manufacturer (first Adare engineering batch completed in Q1 2026) with a targeted commercial launch in H1 2027; the company also expects to initiate the ORCA‑V2 vaping Phase III this year under its CNPV and breakthrough designations. Financially, the company closed a financing providing $180 million upfront plus up to $174 million of milestone-based warrants (exercisable any time prior to and up to 20 trading days following FDA approval). Key clinical/operational metrics cited include analysis of >1,600 Phase III participants, two Phase III double‑blind, placebo‑controlled trials in which both 6‑ and 12‑week courses were statistically significant, planned 52‑week safety/efficacy data later this year, and subgroup results showing 12‑week cytisinicline continuous abstinence of 32.4% versus 6% on placebo (OR 7.5); Achieve said it will commercialize independently with a scalable field force and believes its IP extends into the late 2030s/2040s.

Achieve Life Sciences Risk Analysis

Achieve Life Sciences disclosed 69 risk factors in its most recent earnings report. Achieve Life Sciences reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our planned NDA resubmission following receipt of a CRL citing deficiencies at a third-party manufacturing facility may be delayed, may not adequately address the FDA's concerns, or may not result in approval on the timeline we expect, or at all.Q3, 2026
2.We are currently involved in a dispute with Sopharma AD, or Sopharma, relating to cytisinicline. If we and Sopharma are unable to resolve this dispute, or if the arbitration is resolved unfavorably to us, our rights with respect to the potential commercialization of cytisinicline could be delayed, restricted, or otherwise adversely affected, which could harm our ability to generate value from cytisinicline.Q3, 2026
3.Our transition of finished drug product manufacturing to a new third-party manufacturer could result in delays, supply disruptions, increased costs, and regulatory risk.Q3, 2026

Achieve Life Sciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:SP4P against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
OVIDOVID52Neutral$441.63M-12.50-23.38%―-78.05%63.85%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AVXLAVXL46Neutral$61.88M-4.02-11.43%――73.28%
ACIUACIU45Neutral$216.78M-4.08-104.05%―384.77%38.30%
VNDAVNDA40Underperform$221.92M-0.74-106.94%―8.11%-222.50%
NERVNERV38Underperform$105.65M-0.08167.68%――-1306.84%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:SP4PVNDANERVAVXLACIUOVIDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:SP4P and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:SP4PAchieve Life Sciences5.351.9959.23%
VNDAVanda Pharmaceuticals3.44-1.44-29.55%
NERVMinerva Neurosciences2.00-1.78-47.09%
AVXLAnavex Life Sciences0.59-2.49-80.81%
ACIUAC Immune1.95-1.13-36.69%
OVIDOvid Therapeutics2.200.7147.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.